 |
89 Diseases |  |
30 Trials |
|
30 Trials |  |
3067 News |  |
| «12...17181920212223242526272829 |
- |||||||||| Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
New P3 trial: ELEMENT 2: A Study in Adults With Type 2 Diabetes (clinicaltrials.gov) - Aug 18, 2011
P3, N=606, Completed, Sponsor: Eli Lilly and Company
- |||||||||| Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
New P3 trial, Combination therapy: ELEMENT 1: A Study in Adults With Type 1 Diabetes (clinicaltrials.gov) - Aug 18, 2011
P3, N=400, Completed, Sponsor: Eli Lilly and Company
- ||||||| Bydureon (exenatide XR once-weekly) / AstraZeneca
Trial completion: Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus (clinicaltrials.gov) - Aug 11, 2011
P3, N=427, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed
- Lantus (insulin glargine) / Sanofi, Humalog pen (insulin lispro) / Eli Lilly, NovoLog (insulin aspart) / Novo Nordisk
Enrollment change: ktpump: Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy (clinicaltrials.gov) - Aug 7, 2011
P=N/A, N=24, Completed, Sponsor: Arkansas Children's Hospital Research Institute
Active, not recruiting --> Completed N=30 --> 24
- ||||||| Lantus (insulin glargine) / Sanofi, Lyxumia (lixisenatide) / Zealand Pharma, Sanofi
Trial completion: GetGoal Duo1: 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine (clinicaltrials.gov) - Aug 7, 2011
P3, N=446, Completed, Sponsor: Sanofi
N=30 --> 24 Active, not recruiting --> Completed